A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.

**Authors:** Jayesh Desai FRACP,1* Diwakar Davar MD,2 Sanjeev Deva FRACP,3 Bo Gao FRACP,4 Tianshu Liu MD,5 Marco Matos FRACP,6 Tarek Meniawy FRACP,7 Kenneth J O’Byrne FRACP,8 Meili Sun MD,9 Mark Voskoboynik FRACP,10 Kunyu Yang MD,11 Xinmin Yu MD,12 Xin Chen PhD,13 Yan Dong PhD,14 Hugh Giovinazzo PharmD, PhD,15 Shiangjiin Leaw MD,16 Deepa Patel MD,13 Tahmina Rahman MD,15 Yanjie Wu MD,16 Daphne Day FRACP,17 on behalf of the BGB-A317-A445-101 Clinical Study Team

*Presenting and corresponding author

**Affiliations:**

1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;
2UPMC Hillman Cancer Center, Pittsburgh, PA, USA;
3Auckland City Hospital, Auckland Cancer Trials Centre Governance Group, and Harbour Cancer & Wellness, Auckland, New Zealand;
4Blacktown Cancer and Haematology Centre, Blacktown Hospital, Blacktown, NSW, Australia;
5Affiliated Zhongshan Hospital of Fudan University, Shanghai, China;
6Pindara Private Hospital, Benowa, QLD, Medical Oncology Group of Australia, Sydney, NSW, Australian Medical Council, Canberra, ACT, Medical Board of Queensland, Brisbane, QLD Australia;
7Linear Cancer Research and University of Western Australia, Nedlands, WA, Australia;
8Princess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD, Australia;
9Jinan Central Hospital, Shandong University; Central Hospital Affiliated to Shandong First Medical University, Shandong, China;
10Nucleus Network and Monash University, Melbourne, VIC, Australia;
11Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;
12Zhejiang Cancer Hospital, Hangzhou, China;
13BeiGene USA, Inc., Ridgefield Park, NJ, USA;
14BeiGene USA, Inc., Cambridge, MA, USA;
15BeiGene USA, Inc., San Mateo, CA, USA;
16BeiGene (Shanghai) Co., Ltd., Shanghai, China;
17Department of Medical Oncology, Monash Health, Melbourne, VIC; and Faculty of Medicine, Monash University, Melbourne, VIC, Australia.
**Background:** OX40 is an immune costimulatory receptor, expressed on activated CD4+ and CD8+ T cells, which promotes T cell proliferation and survival in the tumor microenvironment. BGB-A445 is a novel monoclonal antibody (mAb) OX40 agonist that does not compete with endogenous OX40 ligand binding. BGB-A445 has demonstrated antitumor activity as a single agent and in combination with an anti-PD-1 mAb in preclinical studies. Here, we report data from the ongoing dose-escalation part of a multicenter, phase 1 dose escalation/expansion study (NCT04215978) of BGB-A445 alone or in combination with tislelizumab (TIS) in patients (pts) with advanced solid tumors.

**Methods:** Eligible pts were enrolled into seven sequential dose escalation cohorts of BGB-A445 IV as monotherapy (Part A) or five increasing dose levels of BGB-A445 IV in combination with TIS 200 mg IV (Part B) on day 1 of 21-day cycles. Dose escalation was guided by a Bayesian (mTPI-2) approach. This study assessed safety, tolerability, pharmacokinetics (PK) profile, and preliminary antitumor activity (RECIST v1.1).

**Results:** As of August 31, 2022, 59 pts were enrolled in Part A and 32 pts in Part B. Median (range) age was 59 years (28-80) and 61 years (37-75) in Parts A and B, respectively; 26 (44%) and 13 (41%) pts were male, respectively. ≥Grade 3 treatment-emergent AEs (TEAEs) were reported in 24 (41%) and 17 (53%) pts in Parts A and B, respectively; the most commonly reported (≥3 reported) ≥grade 3 TEAEs were gastrointestinal disorders (diarrhea, nausea, and abdominal pain). Serious TEAEs were reported in 23 (39%) pts in Part A and 16 (50%) in Part B. Treatment-related AEs leading to treatment discontinuation were reported in 1 (2%) pt in Part A and 0 (0%) pts in Part B. In Part A, all grade immune-mediated AEs (imAEs) were reported in 11 (19%) pts; no pts reported ≥grade 3 imAEs. In Part B, all grade imAEs were reported in 14 (44%) pts; ≥grade 3 imAEs were reported in 1 (3%) pt (one event each of rash maculopapular and diarrhea). There were no dose-limiting toxicities or concerning patterns of safety/tolerability observed. BGB-A445 PK (maximum concentration [C\text{max}] and area under the curve from day 0 to 21 [AUC\text{0-21}]) were linear and dose proportional in all tested dose ranges. In the efficacy-evaluable population of Parts A (n=50) and B (n=30), respectively, partial response was observed in 2 (4%) pts (unconfirmed) and 7 (23%) pts (confirmed); stable disease in 18 (36%) and 13 (43%) pts (confirmed), and progressive disease in 26 (52%) and 8 (27%) pts.

**Conclusions:** In the dose escalation part of this study, BGB-A445 alone or in combination with TIS was generally well tolerated across all doses in pts with advanced solid tumors, and demonstrated preliminary antitumor activity as both a single and combination agent. The dose expansion part of the study is ongoing in pts with non-small cell lung cancer and head and neck squamous cell carcinoma.